BTIG lowered the firm’s price target on Alector (ALEC) to $5 from $16 and keeps a Buy rating on the shares. The TREM2 activation had little effect in Alzheimer’s disease, not a positive for the world of genome-wide association studies-driven medicine, the analyst tells investors in a research note, adding that the mechanism of ARIA-E may also need to be revisited.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC: